TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2022 Earnings Call Transcript

Adam Waldman: Yes. We’re looking at a number of additional studies, none that we’re prepared to talk about. And we do have, which is probably available. We do have some post commitment studies that we have to do. So we’ll be working on those as well.

Unidentified Analyst: Okay. Thanks.

Operator: Thank you. Ladies and gentlemen, we have reached the end of the question-and-answer session, and I’d now like to turn the floor back over to Mike Weiss for closing comments. Over to you, sir.

Michael Weiss: Great. Thank you. Excellent. And thanks everyone for joining us this morning. As discussed on today’s call, we believe the initial launch activities are progressing well and in many ways ahead of schedule. We believe these early successes position us for an exciting year of commercial execution. We believe BRIUMVI add significant value to the treatment landscape in RMS. We remain committed to supporting the MS community. Thanks again to the patients and their families and healthcare providers who worked with us to get us to this point. And we thank everyone for joining the call today. Have a great day.

Operator: Thank you. Ladies and gentlemen, this concludes today’s teleconference. You may disconnect your lines at this time. Thank you for your participation.